Given the reported significance of SYK in transformation and maintenance of AML, as well as FLT3 kinase inhibitor resistance, and implications of SYK as a potentially important target for AML treatment, we were interested in investigating the ability of midostaurin to inhibit SYK in FLT3 mutant-positive AML. This evidence concerns the gene FLT3 and acute myeloid leukemia.